TISSUEBLUE
Details
- Status
- Prescription
- First Approved
- 2019-12-20
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION
TISSUEBLUE Approval History
What TISSUEBLUE Treats
1 FDA approvalsOriginally approved for its first indication in 2019 .
- Other (1)
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TISSUEBLUE FDA Label Details
ProIndications & Usage
FDA Label (PDF)TissueBlue 0.025% - Indications & Usage Section TissueBlue 0.025% is indicated to selectively stain the internal limiting membrane (ILM). TissueBlue 0.025% is a disclosing agent indicated to selectively stain the internal limiting membrane (ILM).
TISSUEBLUE Patents & Exclusivity
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.